PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more
PanGen Biotech Inc (222110) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.122x
Based on the latest financial reports, PanGen Biotech Inc (222110) has a cash flow conversion efficiency ratio of -0.122x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.66 Billion) by net assets (₩30.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PanGen Biotech Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how PanGen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PanGen Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PanGen Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Laseroptek Co., Ltd.
KQ:199550
|
0.008x |
|
PT Intra GolfLink Resorts Tbk
JK:GOLF
|
0.003x |
|
Cohiba Minerals Limited
PINK:CHKMF
|
-0.031x |
|
Thanh Thanh Cong Tourist JSC
VN:VNG
|
N/A |
|
Prizma Pres Matbaacilik Yayincilik Sanayi ve Ticaret AS
IS:PRZMA
|
0.007x |
|
Nido Education Ltd
AU:NDO
|
0.049x |
|
Arizona Silver Exploration Inc
OTCQB:AZASF
|
-0.002x |
|
Nippon Indosari Corpindo Tbk
JK:ROTI
|
0.047x |
Annual Cash Flow Conversion Efficiency for PanGen Biotech Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of PanGen Biotech Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩24.91 Billion | ₩2.99 Billion | 0.120x | +143.67% |
| 2023-12-31 | ₩12.57 Billion | ₩-3.45 Billion | -0.275x | -35.00% |
| 2022-12-31 | ₩17.22 Billion | ₩-3.50 Billion | -0.203x | -29.11% |
| 2021-12-31 | ₩21.10 Billion | ₩-3.32 Billion | -0.158x | +52.17% |
| 2020-12-31 | ₩14.21 Billion | ₩-4.68 Billion | -0.329x | -65.73% |
| 2019-12-31 | ₩18.43 Billion | ₩-3.66 Billion | -0.199x | +4.56% |
| 2018-12-31 | ₩26.94 Billion | ₩-5.61 Billion | -0.208x | -891.15% |
| 2017-12-31 | ₩31.31 Billion | ₩-657.84 Million | -0.021x | +82.93% |
| 2016-12-31 | ₩35.31 Billion | ₩-4.35 Billion | -0.123x | +49.74% |
| 2015-12-31 | ₩6.56 Billion | ₩-1.61 Billion | -0.245x | -95.31% |
| 2014-12-31 | ₩10.69 Billion | ₩-1.34 Billion | -0.125x | -- |